Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

9 Months Ended

Apr. 30, 2019

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended April 30, 2019	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	11,751		$	7,911			—			—		$	19,662

Operating costs, expenses and legal settlements, net:
Cost of revenues		10,963			3,397			—			—			14,360
Research and development		31			527		$	223			—			781
Selling, general and administrative		5,960			2,923			—		$	2,037			10,920
Legal fee expense		35			16			—			206			257
Legal settlements, net		—			(28,925	)		—			—			(28,925	)
Total operating costs, expenses and legal settlements, net		16,989			(22,062	)		223			2,243			(2,607	)

Operating income (loss)		(5,238	)		29,973			(223	)		(2,243	)		22,269

Other income (expense):
Interest		(18	)		19			—			257			258
Other		6			—			—			64			70
Foreign exchange loss		—			(332	)		—			—			(332	)
Income (loss) before income taxes	$	(5,250	)	$	29,660		$	(223	)	$	(1,922	)	$	22,265

Depreciation and amortization included above	$	440		$	340		$	—		$	58		$	838

Share-based compensation included in above:
Selling, general and administrative		40			24			—			135			199
Total	$	40		$	24		$	—		$	135		$	199

Capital expenditures	$	120		$	446		$	—		$	—		$	566

Three months ended April 30, 2018	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	17,737		$	7,493			—			—		$	25,230

Operating costs and expenses:
Cost of revenues		10,995			3,562			—			—			14,557
Research and development		—			576		$	223			—			799
Selling, general and administrative		6,252			2,970			—		$	1,799			11,021
Legal fee expense		25			19			—			1,607			1,651
Total operating costs and expenses		17,272			7,127			223			3,406			28,028

Operating income (loss)		465			366			(223	)		(3,406	)		(2,798	)

Other income (expense):
Interest		(22	)		12			—			237			227
Other		15			2			—			—			17
Foreign exchange loss		—			(462	)		—			—			(462	)
Income (loss) before income taxes	$	458		$	(82	)	$	(223	)	$	(3,169	)	$	(3,016	)

Depreciation and amortization included above	$	437		$	358		$	—		$	20		$	815

Share-based compensation included in above:
Selling, general and administrative		26			17			—			161			204
Total	$	26		$	17		$	—		$	161		$	204

Capital expenditures	$	465		$	96		$	—		$	—		$	561

Nine months ended April 30, 2019	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	38,048		$	22,201			—			—		$	60,249

Operating costs, expenses and legal settlements, net:
Cost of revenues		32,956			10,391			—			—			43,347
Research and development		31			1,645		$	666			—			2,342
Selling, general and administrative		18,220			8,828			—		$	6,339			33,387
Legal fee expense		109			24			—			2,567			2,700
Legal settlements, net		—			(28,925	)		—			—			(28,925	)
Total operating costs, expenses and legal settlements, net		51,316			(8,037	)		666			8,906			52,851

Operating income (loss)		(13,268	)		30,238			(666	)		(8,906	)		7,398

Other income (expense):
Interest		(51	)		49			—			761			759
Other		17			—			—			232			249
Foreign exchange loss (gain)		—			(530	)		—			—			(530	)
(Loss) income before income taxes	$	(13,302	)	$	29,757		$	(666	)	$	(7,913	)	$	7,876

Depreciation and amortization included above	$	1,217		$	1,025		$	—		$	130		$	2,372

Share-based compensation included in above:
Selling, general and administrative		118			74			—			533			725
Total	$	118		$	74		$	—		$	533		$	725

Capital expenditures	$	883		$	524		$	—		$	6,147		$	7,554

Nine months ended April 30, 2018	Clinical Services			Products		Therapeutics			Other			Consolidated
Revenues	$	56,001		$	22,257		—			—		$	78,258

Operating costs and expenses:
Cost of revenues		34,767			10,828		—			—			45,595
Research and development		—			1,690	$	668			—			2,358
Selling, general and administrative		18,454			8,476		—		$	6,045			32,975
Legal fee expense		46			47		—			3,689			3,782
Total operating costs and expenses		53,267			21,041		668			9,734			84,710

Operating income (loss)		2,734			1,216		(668	)		(9,734	)		(6,452	)

Other income (expense):
Interest		(70	)		35		—			604			569
Other		32			10		—			44			86
Foreign exchange loss		—			143		—			—			143
Income (loss) before income taxes	$	2,696		$	1,404	$	(668	)	$	(9,086	)	$	(5,654	)

Depreciation and amortization included above	$	1,254		$	1,039	$	—		$	57		$	2,350

Share-based compensation included in above:
Selling, general and administrative		86			61		—			470			617
Total	$	86		$	61	$	—		$	470		$	617

Capital expenditures	$	1,459		$	167	$	—		$	—		$	1,626